Introduction {#S1}
============

Normal wound healing is a complex process composed of multiple sequential, albeit overlapping, phases (hemostasis, inflammatory, proliferative, and remodeling/maturation) that involve finely tuned interactions between many molecular, cellular, physiological, biochemical and mechanical factors ([@B7]; [@B56]; [@B2]). When the remodeling/maturation phase is deranged, scars can start to grow and spread abnormally, thus resulting in the pathological scars known as keloids and hypertrophic scars ([@B16]). Pathologically, these abnormal scars are characterized by excessive deposition of extracellular matrix (ECM) ([@B1]). To date, the mechanisms involved in the remodeling/maturation phase of normal and abnormal wound healing have been relatively poorly researched. This lack of knowledge has hampered the development of strategies that can prevent abnormal scar formation and/or effectively treat these scars once they have formed ([@B31]).

Multiple cell types play key roles in normal and abnormal wound healing: of particular interest are immune cells, fibroblasts, myofibroblasts, vascular endothelial cells (VECs), and mural cells (vascular smooth muscle cells and pericytes). In relation to immune cells, it is thought that abnormal prolongation of the inflammation into the scar remodeling phase is a crucial mechanism that underlies pathological scar formation and progression ([@B9]; [@B43]). Similarly, fibroblasts and myofibroblasts, which lay down ECM, are major players in the excessive fibrosis that characterizes pathological scarring. Finally, VECs and their extensive interactions with the surrounding mural cells appear to play key inductive roles in scar pathogenesis: there is now considerable evidence that their abnormal functions and interactions with immune and fibrotic cells may promote both the inflammation and ECM deposition in abnormal scarring. For example, in keloids, the metabolism of the ECM is profoundly abnormal, resulting in 'keloidal collagen', which are thick and complex collagen bundles that eventually become extremely interconnected ([@B17]; [@B38]). These pathological changes are accompanied by deranged angiogenesis, as shown by low capillary density, microvessel occlusion and luminal flattening, and a chaotic microvessel architecture characterized by relatively large capillaries with few connections with the smaller capillaries. Despite the relatively high blood flow in keloids (as shown by Doppler), it is likely that this faulty angiogenesis leads to local hypoxia that in turn promotes aberrant ECM metabolism ([@B52]; [@B29]). This hypothesis is supported by the fact that two effective treatments for keloids, namely, radiotherapy and laser therapy, act by suppressing angiogenesis and by destroying the poorly functioning blood vessels; the latter promotes the function of the stable blood vessels and thereby eliminates hypoxia ([@B45]; [@B44]).

There are also other indirect lines of evidence that suggest that VEC dysfunction plays an important role in keloid pathogenesis ([@B44]). For example, patients with hypertension tend to have worse keloids than nonhypertensive patients ([@B4]). Moreover, patients with keloids have lower endothelial function than patients without keloids, as measured by reactive hyperemia peripheral arterial tonometry ([@B42]). It is also possible that the familial tendency of keloids and the fact that black people develop keloids much more readily than Caucasians relate to the presence of one or more single nucleotide polymorphisms that promote VEC dysfunction: one recent candidate is a variant of the N-acylsphingosine amidohydrolase-1 (ASAH1) gene, which is expressed by VECs and mural cells ([@B49]).

Despite these observations, there are few functional analyses of the VECs from keloids. This reflects technical difficulties associated with isolating endothelial cells from tissues with excessive fibrosis. As a result, the roles of VECs in keloid formation and progression and their underlying molecular mechanisms remain poorly understood. We recently found a method for successfully isolating live endothelial cells from keloid tissues: the tissue is first gently digested and the resulting free cells are separated by magnetic sorting. The aim of this study was to analyze the gene expression profiles of keloid VECs to identify the factors that could contribute to (i) keloid formation and (ii) pathological interactions between angiogenesis, inflammation, and fibrosis.

Materials and Methods {#S2}
=====================

Patients and Tissues {#S2.SS1}
--------------------

Tissue samples were obtained during surgical procedures that were performed between May 2016 and October 2016 at Nippon Medical School Hospital, Tokyo, Japan. Keloid tissues were obtained from the central region of surgically resected keloids. Normal skin samples were obtained from the 'dog ear' tissues (bulges of excess skin) that were left after reconstructive surgery and that had to undergo additional resection in patients without keloids or any systemic complications. The study was approved by the Institutional Review Board of Nippon Medical School, Tokyo, Japan and adhered to the principles of the Declaration of Helsinki and its revisions (27-02-560). Written informed consent was obtained from each study participant.

Tissue Dissociation {#S2.SS2}
-------------------

The resected tissue specimens were placed in Dulbecco's modified Eagle's medium (DMEM; Fujifilm Wako, Osaka, Japan) supplemented with Antibiotic-Antimycotic (ABAM; Thermo Fisher Scientific, Waltham, MA, United States). The specimens were transported to the laboratory and cut into 1 × 2-cm with full thickness. The VECs were then isolated by washing the tissues three times with DMEM supplemented with ABAM, mincing the tissues into approximately 3-mm^3^ pieces with scissors, and digesting the mix with Skin Dissociation Kit (Miltenyi Biotech, Bergish Gladbach, Germany) according to the manufacturer's instructions. Briefly, this process involved placing the tissue mix in a gentleMACS C tube together with DMEM containing 1% bovine serum albumin (BSA), Enzyme P, Enzyme D, and Enzyme A (Miltenyi Biotech). The mixture was then allowed to digest for approximately 1 hour in a GentleMACS Octo Dissociator with Heaters (Miltenyi Biotech). Subsequently, the cells were squeezed through 100-μm Cell Strainers (Corning, Corning, NY, United States) and harvested by centrifugation (300 *g*, 10 min, 4°C). Thereafter, PEB buffer composed of phosphate-buffered saline (PBS), pH 7.2, 0.5% BSA, and 2 mM EDTA was added to the cells and mixed well.

Magnetic Sorting of VECs {#S2.SS3}
------------------------

The isolated cells were sorted by the Miltenyi Biotech magnetic sorting system as shown in [Figure 1](#F1){ref-type="fig"}. The first step was to add Anti-CD45 MicroBeads and Anti-Fibroblast MicroBeads (the latter are conjugated to monoclonal mouse anti-human fibroblast antibodies and mainly target CD44) (Miltenyi Biotech) to the cells and to incubate the mixture at room temperature for 10 min. Anti-CD31-PE antibodies (Miltenyi Biotech) were then added, followed by incubation at 4°C in the dark. Subsequently, the cell suspension was subjected to magnetic sorting using LS Columns (Miltenyi Biotech) that had been washed three times with PEB. The cells that passed through the column were collected and centrifuged (300 *g*, 10 min, 4°C), after which the supernatant was removed. Anti-PE-MicroBeads (Miltenyi Biotech) and PEB were then added to the cells and mixed well. The resulting cell suspensions were loaded onto thrice-washed LS Columns and the cells that passed through were discarded. After removing the column from the magnet, the cells were washed out into a tube and then, to increase the purity of the VECs, passed through another LS column. Thereafter, the resulting suspension was immediately placed in RNAlater (Thermo Fisher Scientific). Some of the suspension was analyzed by flow cytometry using FACScan (BD Biosciences, Franklin Lakes, NJ, United States) to determine the purity of the VECs.

![Schematic depiction of the magnetic sorting procedure used to isolate the skin vascular endothelial cells. Magnetic sorting was performed in two steps that separated the CD31-positive cells from the fibroblasts and CD45-positive cells.](fcell-08-00658-g001){#F1}

RNA Extraction {#S2.SS4}
--------------

Vascular endothelial cells RNA was isolated by using RNeasy Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The integrity and overall quality of the total RNA were checked by using Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, United States).

Microarray Analysis {#S2.SS5}
-------------------

Vascular endothelial cells gene expression analysis was performed by using Agilent SurePrint G3 Human Gene Expression 8 × 60 K ver3.0 (Agilent Technologies) according to the manufacturer's instructions (One-Color Microarray-Based Gene Expression Analysis Protocol Version Jan. 2012; Agilent Technologies). In brief, cyanine-3 (Cy3)-labeled cRNA was prepared from 75 ng RNA by using the One-Color Low Input Quick Amp labeling kit (Agilent Technologies. Dye incorporation and cRNA yield were checked with a NanoDrop spectrophotometer (Thermo Fisher Scientific). For hybridization, 600 ng of Cy3-labeled cRNA was fragmented at 60°C for 30 min. On completion of the fragmentation reaction, 25 μl of 2X Agilent hybridization buffer was added to the fragmentation mixture and hybridized for 17 h at 65°C in a rotating Agilent hybridization oven. After hybridization, the microarrays were washed with GE Wash Buffer. Slides were scanned after washing on the Agilent Technologies Microarray scanner. The fluorescence intensities on scanned images were extracted and preprocessed by Agilent Feature Extraction software (v10.7.3.1). The raw signals were normalized using the percentile shift normalization method; the value was set at 75th percentile and log-transformed. Universal Human Reference RNA (Agilent Technologies) was used as the control.

Quantitative RT-PCR (qRT-PCR) {#S2.SS6}
-----------------------------

cDNA was synthesized using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). qRT-PCR assays were performed using an ABI Prism 7500 System (Applied Biosystems, Foster City, CA, United States) with Applied Biosystems TaqMan Gene Expression Assays (SERPINA3, Hs00153674_m1; LAMC2, Hs01043717_m1; GAPDH, Hs03929097_g1) and TaqMan Gene Expression Master Mix (Thermo Fisher Scientific). For each primer set, the optimal dilution was determined and melting curves were used to determine the amplification specificity. GAPDH served as the internal control after it was found to validate several expression assays. Relative expression was calculated by using the 2^--ΔΔCt^ method with correction for different amplification efficiencies.

Immunohistochemistry {#S2.SS7}
--------------------

Formalin-fixed paraffin-embedded slices of the keloid and normal tissues were baked for 30 min at 58°C, deparaffinized in xylene, rehydrated through graded alcohol, and antigen-retrieved at 98°C in a water bath for 30 min in sodium citrate buffer (10 mM sodium citrate, pH 6.0). The slides were then immersed in 0.3% hydrogen peroxide diluted in methanol for 20 min to block endogenous peroxidase activity. Subsequently, they were preincubated with 5% bovine serum albumin (BSA) at 15--20°C for 15 min to reduce non-specific reactions. Thereafter, the slides were incubated with anti-SERPINA3 (1:50, Abcam, Cambridge, MA, United States) or anti-LAMC2 (1:200, GeneTex, Irvine, CA, United States) antibody. The slides were sequentially incubated with a secondary antibody, Histofine Simple Stain MAX-PO (MULTI) (Nichirei Biosciences, Tokyo, Japan) at 15--20°C for 30 min, followed by staining with DAB (Dako, Glostrup, Denmark). Finally, the slides were counterstained with Mayer's hematoxylin, dehydrated in graded concentrations of ethanol, and mounted.

Lipopolysaccharide (LPS) Stimulation of a Dermal VEC Line {#S2.SS8}
---------------------------------------------------------

The HMEC-1 cell line is derived from human dermal microvascular endothelium. It was purchased from ATCC (Manassas, VA, United States) and cultured in MCDB131 medium supplemented with 10 ng/mL epidermal growth factor, 1 μg/mL hydrocortisone, 10 mM glutamine, and 10% fetal bovine serum (FBS). LPS from E. coli O111 was purchased from Fujifilm Wako (Osaka, Japan). The HMEC-1 cells were plated in a 24-well plate at densities of 4 × 10^4^ cells/well and grown until sub-confluency. The cells were then cultured with or without 1 μg/ml LPS for 15 h ([@B15]), after which the cells were harvested for RNA extraction and qRT-PCR.

Effect of Laminin-5 on Dermal Fibroblast Proliferation and Apoptosis {#S2.SS9}
--------------------------------------------------------------------

Laminin-5 consists of α, β, and γ subunits; the γ subunit is encoded by LAMC2 ([@B23]). Normal human dermal fibroblasts (NHDFs) were purchased from TaKaRa (Shiga, Japan) and cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% FBS. They were plated in 96-well plates at density of 1 × 10^4^ cells/well and grown for 24 h. The cells were then treated with or without 0.5 μg/ml of human recombinant laminin-5 (also known as laminin-332) (Oriental Yeast, Tokyo, Japan) in DMEM containing 2% FBS for 15 h ([@B6]). Cell proliferation and apoptosis were assessed by using ApoLive-Glo Multiplex Assay (Promega, Madison, WI, United States) according to the manufacturer's instructions. Thus, the cells were incubated with Viability Reagent for 30 min at 37°C and fluorescence was measured at the wavelength set of 400Ex/505Em. The cells were then incubated with Caspase-Glo 3/7 Reagent for 30 min at room temperature and luminescence was measured.

Statistical Analysis {#S2.SS10}
--------------------

Comparisons between the two groups in terms of continuous variables were performed with Student's *t*-test (if the data were normally distributed) or with the non-parametric Mann-Whitney-Wilcoxon (if the data were not normally distributed). Statistical significance was set at *p* \< 0.05, unless otherwise specified. Statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R 2.13.0 (R Foundation for Statistical Computing, Vienna, Austria). More precisely, EZR is a modified version of R commander (version 1.6-3) that was designed to add statistical functions that are frequently used in biostatistics.

Results {#S3}
=======

Efficiency and Accuracy of VECs Isolation and RNA Extraction {#S3.SS1}
------------------------------------------------------------

The magnetic sorting system shown in [Figure 1](#F1){ref-type="fig"} successfully and efficiently isolated live VECs from keloid and normal skin samples. Total RNAs were then obtained from the VECS of five keloid samples (KVECs) and six normal skin samples (NVECs). The clinical characteristics of the patients, the purity of the isolated VECs (as measured by flow cytometry), and the integrity of the extracted RNAs are presented in [Table 1](#T1){ref-type="table"}. VEC purity ranged from 81.8% to 98.6%. Representative flow cytometric plots and histograms are shown in [Figure 2](#F2){ref-type="fig"}. RNA integrity (as expressed by RNA Integrity Number) ranged between 6.4 and 9.4.

###### 

Characteristics of the patients, vascular endothelial cell (VEC) purity, and RNA integrity.

  Sample No.                Range of age   Area             VECs (% of cells in the sample)   RIN
  ------------------------- -------------- ---------------- --------------------------------- -----
  **Keloids**                                                                                 
  K-1                       26--30         Shoulder         97.5                              8.6
  K-2                       60--65         Anterior chest   93.4                              8.8
  K-3                       60--65         Lower abdomen    98.6                              9.4
  K-4                       20--25         Upper limb       98.3                              9.3
  K-5                       56--60         Lower abdomen    98.5                              8.3
  **Normal skin samples**                                                                     
  N-6                       76--80         Eyelid           85.9                              7.5
  N-7                       70--75         Thigh            96.8                              6.4
  N-8                       60--65         Dorsal           95.5                              9.2
  N-9                       76--80         Eyelid           97.4                              9.1
  N-10                      70--75         Eyelid           81.8                              6.8
  N-11                      60--65         Lower abdomen    93.9                              7.0

RIN, RNA integrity number.

![Flow cytometric evaluation of the efficiency with which skin vascular endothelial cells were isolated. Representative flow cytometry plots and histograms of total dispersed cells before sorting (upper) and after sorting (lower) are shown. Very pure CD31-positive cell samples were obtained by magnetic sorting.](fcell-08-00658-g002){#F2}

Microarray Analysis Followed by Hierarchical Clustering and Principal Component Analysis {#S3.SS2}
----------------------------------------------------------------------------------------

The VEC RNAs were subjected to microarray analysis followed by hierarchical clustering and principal component analysis (PCA): this allowed us to visualize significant gene expression differences between the KVECs and NVECs. Hierarchical clustering showed that the KVECs and NVECs largely fell into two separate clusters: the exception was one KVEC sample (K5), which formed a subcluster that branched out from the main KVEC cluster with two NVEC samples (N10 and N11). Thus, the mRNA expression profiles of the KVECs were largely different from those of the NVECs ([Figure 3A](#F3){ref-type="fig"}). PCA then showed that the KVECs were located a marked distance away from the NVECs ([Figure 3B](#F3){ref-type="fig"}, upper plot); this trend was confirmed by a different 3-dimensional representation of the data ([Figure 3B](#F3){ref-type="fig"}, lower plot). Thus, while there was substantial sample variability, the KVECs clearly had different molecular phenotypes compared to the NVECs.

![Hierarchical clustering and principal component analysis (PCA) of the vascular endothelial cell (VEC) samples. **(A)** The expression patterns of all samples are shown in the heatmap. The sample numbers of the normal VECs (NVECs) and keloid VECs (KVECs) are indicated at the top. On hierarchical clustering, the KVECs and NVECs generally fell into two separate clusters. **(B)** PCA plots that visualize the distribution of KVECs and NVECs in terms of gene expression pattern. The KVECs were distributed close to each other and away from the NVECs. As a result, the KVECs could be divided from the NVECs by the indicated green broken line. The upper and lower plots indicate the distributions from two different 3-dimensional viewpoints.](fcell-08-00658-g003){#F3}

Extraction of Genes and Network Analysis {#S3.SS3}
----------------------------------------

Relative to NVECs, 15 and three genes in KVECs were respectively up- and down-regulated (as determined by Welch's *t*-test; all *p* \< 0.05) ([Table 2](#T2){ref-type="table"}). [Table 3](#T3){ref-type="table"} lists the 10 genes that exhibited the greatest up- or downregulation in KVECs relative to NVECs. Of these, we focused on two factors, SERPINA3 and LAMC2, which are known to be involved in ECM metabolism and inflammation, respectively ([@B5]; [@B32]). SERPINA3 and LAMC2 exhibited 16- and 11-fold upregulation in the microarray analysis, respectively ([Table 3](#T3){ref-type="table"}). To visualize whether these genes play an important role in KVEC gene regulation, we performed network analysis with the 74 and 80 genes that were, respectively, up- and down-regulated in KVECs by more than 5-fold. Both SERPINA3 and LAMC2 were located near the center of the network, which suggests that they may play important roles in KVEC phenotype ([Figure 4](#F4){ref-type="fig"}).

###### 

Genes that were expressed at significantly (*p* \< 0.05) higher or lower levels in KVECs compared to in NVECs (as determined by using Welch's *t-*test).

  Probe Name          Gene Abbreviation   Gene Name                                                                 Corrected p-value
  ------------------- ------------------- ------------------------------------------------------------------------- -------------------
  **Upregulated**                                                                                                   
  A_23_P103256        CFHR3               complement factor H-related 3                                             0.010
  A_33_P3304170       PIK3CG              phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma   0.010
  A_23_P41145         FAM3D               family with sequence similarity 3, member D                               0.018
  A_33_P3367692       CFH                 complement factor H                                                       0.018
  A_19_P00808586      LINC01085           long intergenic non-protein coding RNA 1085                               0.018
  A_33_P3286349       DNAAF3              dynein, axonemal, assembly factor 3                                       0.018
  A_33_P3318288       CFH                 complement factor H                                                       0.018
  A_23_P114740        CFH                 complement factor H                                                       0.025
  A_32_P35969         CHRNA7              cholinergic receptor, nicotinic, alpha 7 (neuronal)                       0.026
  A_23_P49559         GPR142              G protein-coupled receptor 142                                            0.026
  A_23_P79251         EHD3                EH-domain containing 3                                                    0.026
  A_33_P3333158       CPXM2               carboxypeptidase X (M14 family), member 2                                 0.026
  A_23_P124927        RGS14               regulator of G-protein signaling 14                                       0.035
  A_23_P57110         SLC52A3             solute carrier family 52 (riboflavin transporter), member 3               0.042
  A_33_P3245631       TTC39A              tetratricopeptide repeat domain 39A                                       0.050
  **Downregulated**                                                                                                 
  A_33_P3245290       AQP7P1              aquaporin 7 pseudogene 1                                                  0.020
  A_21_P0005172       LINC00472           long intergenic non-protein coding RNA 472                                0.026
  A_22_P00017310      MIR99AHG            mir-99a-let-7c cluster host gene (non-protein coding)                     0.044

KVEC, keloid vascular endothelial cell; NVEC, normal vascular endothelial cell.

###### 

Genes that were highly up- or down-regulated in KVECs compared to in NVECs.

  Probe Name          Gene Abbreviation   Gene Name                                                                             FC
  ------------------- ------------------- ------------------------------------------------------------------------------------- --------
  **Upregulated**                                                                                                               
  A_33_P3211198       NCMAP               noncompact myelin associated protein                                                  30.51
  A_23_P137797        RYR2                ryanodine receptor 2 (cardiac)                                                        18.51
  A_23_P2920          SERPINA3            serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3   16.08
  A_23_P160214        TTC39A              tetratricopeptide repeat domain 39A                                                   12.57
  A_23_P160968        LAMC2               laminin, gamma 2                                                                      11.01
  A_19_P00323692      XIST                X inactive specific transcript (non-protein coding)                                   10.86
  A_33_P3399788       SERPINA3            serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3   10.81
  A_23_P69154         FAM198A             family with sequence similarity 198, member A                                         10.75
  A_23_P94902         KCTD8               potassium channel tetramerization domain containing 8                                 10.54
  A_23_P29773         LAMP3               lysosomal-associated membrane protein 3                                               10.44
  **Downregulated**                                                                                                             
  A_23_P324384        RPS4Y2              ribosomal protein S4, Y-linked 2                                                      −40.26
  A_33_P3224331       DDX3Y               DEAD (Asp-Glu-Ala-Asp) box helicase 3, Y-linked                                       −23.37
  A_23_P259314        RPS4Y1              ribosomal protein S4, Y-linked 1                                                      −21.81
  A_23_P15786         KRT25               keratin 25, type I                                                                    −19.70
  A_32_P98072         TCHH                trichohyalin                                                                          −15.51
  A_23_P99044         KRT71               keratin 71, type II                                                                   −15.21
  A_23_P97141         RGS1                regulator of G-protein signaling 1                                                    −13.98
  A_23_P78201         KRT35               keratin 35, type I                                                                    −13.10
  A_24_P234768        HTR4                5-hydroxytryptamine (serotonin) receptor 4, G protein-coupled                         −11.24
  A_23_P362694        FDCSP               follicular dendritic cell secreted protein                                            −10.19

KVEC, keloid vascular endothelial cell; NVEC, normal vascular endothelial cell.

![Network analysis with the 74 and 80 genes that were, respectively, up- and down-regulated by more than 5-fold in keloid vascular endothelial cells. SERPINA3 (red) and LAMC2 (yellow) are located near the center of the network.](fcell-08-00658-g004){#F4}

Validation of Microarray Data Regarding SERPINA3 and LAMC2 mRNA Expression {#S3.SS4}
--------------------------------------------------------------------------

We performed qRT-PCR to verify the microarray data. Given the relatively large variation between samples, qRT-PCR was performed using RNA extracted from six NVECs and seven KVECs: thus, two additional KVEC samples from different patients were added to the five KVEC samples that were used to generate the microarray analysis data. The two additional KVEC samples were from patients aged 36--40 years whose keloids were on the anterior chests (VEC purities were 98.8% and 99.1%). The qRT-PCR analysis confirmed that the KVECs had significantly higher mRNA expression levels of both SERPINA3 and LAMC2 compared to NVECs ([Figures 5A,B](#F5){ref-type="fig"}).

![Validation of the microarray data by quantitative RT-PCR. The relative mRNA expression levels of SERPINA3 **(A)** and LAMC2 **(B)** in keloid vascular endothelial cells (KVECs) (*n* = 7) and normal vascular endothelial cells (NVECs) (*n* = 6) are shown. All values in this figure represent the mean ± SD.](fcell-08-00658-g005){#F5}

Histological Validation of SERPINA3 and LAMC2 Protein Expression in Blood Vessels of Skin Samples {#S3.SS5}
-------------------------------------------------------------------------------------------------

Three keloids and three normal skin specimens were obtained by surgery from a separate cohort of patients. The keloid samples were obtained from patients whose keloids were on the lower abdomen (age 56--60 years) and anterior chests (age 61--65 and 76--80 years). The three non-keloid samples were from patients aged 11--15, 21--25, and 71--75 years. Immunohistochemical analysis of the six samples showed that all of the keloids had greater protein expression of both SERPINA3 and LAMC2 in the blood vessels than the normal skin samples. Representative images are shown in [Figures 6A,B](#F6){ref-type="fig"}. These results are consistent with the microarray data.

![Immunohistochemical validation of **(A)** SERPINA3 and **(B)** LAMC2 protein expression in the blood vessels of keloid and normal skin tissues. Representative histological images are shown. Arrows indicate the blood vessels in the dermis. LPF, low-power field, HPF, high-power field. Scale bars: LPF, 50 μm, HPF, 20 μm.](fcell-08-00658-g006){#F6}

Inflammation-Induced Dysfunction Increases SERPINA3 and LAMC2 Expression in VECs but LAMC2 Does Not Affect Fibroblast Proliferation {#S3.SS6}
-----------------------------------------------------------------------------------------------------------------------------------

To assess whether SERPINA3 and LAMC2 could participate in keloid pathogenesis, we asked whether activation with LPS changes the SERPINA3 and LAMC2 expression exposed to it, blood vessels exhibit hyperpermeability, and VECs adopt proinflammatory leukocyte-recruiting phenotypes, including the production of proinflammatory cytokines, chemokines, and adhesion molecules ([@B53]; [@B15]). Indeed, LPS treatment of the VEC line with LPS caused it to upregulate SERPINA3 and LAMC2 expression ([Figure 7A](#F7){ref-type="fig"}). This is consistent with the upregulated expression of these genes in KVECs ([Figures 5](#F5){ref-type="fig"}, [6](#F6){ref-type="fig"}).

![*In vitro* study on the biological functions of SERPINA3 and LAMC2 in vascular endothelial cells and fibroblasts. **(A)** A human dermal vascular endothelial cell line (HMEC-1) was treated with or without 1 μg/ml lipopolysaccharide (LPS) for 15 h (*n* = 6). The relative mRNA expression levels of SERPINA3 and LAMC2 in the cells was determined. **(B)** Normal human dermal fibroblasts (NHDF) were treated with or without 0.5 μg/ml laminin-5 for 15 h (*n* = 10). The relative cell proliferation and apoptosis was measured. All values in this figure represent the mean ± SD. \*\* *p* \< 0.01.](fcell-08-00658-g007){#F7}

Since secreted LAMC2 promotes the proliferation and survival of cancer cells ([@B19]; [@B50]), and excessive fibroblast proliferation and insufficient apoptosis play an important role in keloid pathogenesis ([@B18]), we speculated that LAMC2-overexpressing VECs could secrete LAMC2 and thereby promote local fibroblast proliferation and survival. However, we observed that the LAMC2-treated fibroblasts did not exhibit increased proliferation or resistance to apoptosis ([Figure 7B](#F7){ref-type="fig"}).

Discussion {#S4}
==========

Keloids and hypertrophic scars are caused by genetic and environmental factors; the environmental factors can be divided further into local and systemic factors. In terms of genetic factors, keloids associate with single nucleotide polymorphisms; in addition, people with dark skin are 15-fold more likely to develop keloids than people with lighter skin ([@B39]; [@B40]). The local factors that promote pathological scar development are, like the genetic factors, well-studied and include the elastic tension on the skin and mechanical stress ([@B3]). Much less well-understood are the systemic factors that associate with keloidogenesis; these include adolescence, pregnancy ([@B46]; [@B27]), and endothelial dysfunction. With regard to the latter factor, mounting evidence now suggests that disturbed endothelial function may in fact play a key role in initiating and augmenting the pathogenic activities of other important cellular players in pathological scarring. For example, our recent studies show that poor endothelial function and hypertension associate with keloid development and aggravation ([@B4]; [@B42]). These clinical observations led us to analyze the gene expression in VECs from keloid patients, with the aim of identifying local cell interactions or microenvironments that could be exploited therapeutically.

The proper maintenance of vascular integrity requires that VECs interact with and adhere to the ECM. Along with endothelial cell proliferation and migration, these interactions between VECs and the ECM also play an important role in the angiogenesis that participates in crucial processes such as osteogenesis, tumor growth, and wound healing ([@B30]; [@B35]; [@B8]). It is known that during the aberrant wound healing that leads to pathological scarring, VEC proliferation and new blood vessel formation may be shaped by immune and other factors such as endothelin-1, vascular endothelial growth factor, platelet-derived growth factor, and transforming growth factor-β. Notably, VECs may also secrete the latter factor, thereby activating nearby fibroblasts and initiating fibrotic reactions ([@B26]; [@B54]). This pathogenic role of VECs is supported by our finding that the abundant hyalinized keloidal collagen that characterizes keloids appear to arise from the perivascular area ([@B38]). Based on these reports, we postulated that when inflammation occurs, VECs may play important roles in regulating the behavior of other cell types and tissue homeostasis. In the present study, we identified the genes that are up- or down-regulated in KVECs and then focused on SERPINA3 and LAMC2, both of which are sharply up-regulated in KVECs and thus may contribute to keloid pathogenesis.

The serpin family consists of a functionally diverse set of proteins that are named after their function as serine proteinase inhibitors ([@B47]). Serpins play important roles in inflammation, immunity, coagulation, dementia, and cancer and can be potential biomarkers and therapeutic targets for disease ([@B24]). SERPINA3 is also known as α1-antichymotrypsin: it is an acute phase reactive protein and a serpin family member. Although its biological role in wound healing remains unknown, SERPINA3 appears to reduce leukocyte protease-mediated tissue damage ([@B21]). Serpins also inhibit neutrophil-derived cathepsin G, which is a potent regulator of inflammatory processes and is directly involved in the degradation of ECM molecules that are essential for skin repair ([@B10]), including collagen ([@B13]; [@B25]), elastin ([@B36]), and fibronectin ([@B11]; [@B33]). Furthermore, SERPINA3 is a potent inhibitor of matrix metalloproteinase type 9 activation in human wound healing ([@B22]; [@B48]). Our data showed that SERPINA3 is upregulated by 16-fold in KVECs compared to NVECs; this upregulation in VECs was observed at both the mRNA and protein level. Notably, we also found that when normal VECs become inflamed and dysfunctional due to exposure to LPS, their expression of SERPINA3 rises significantly. Thus, given its roles in inflammation, SERPINA3 may also act in keloid pathogenesis by altering local immune responses.

Laminins are large heterotrimers that constitute the basement membrane in ECM. They are composed of α, β, and γ subunits ([@B57]). VECs attach to several ECM components, including fibronectin, collagen, and laminin ([@B28]). Laminins not only directly affect leukocyte migration, they also indirectly influence endothelial barrier function by modulating endothelial barrier properties ([@B51]). LAMC2 is the short arm of Laminin-5. It shapes cell motility and growth, thereby affecting morphogenic events ([@B41]; [@B19]). The targeted degradation of laminin-5 and LAMC2 by matrix metalloproteinases promote cell migration ([@B20]; [@B12]). Significantly, LAMC2 induces the shrinkage of VECs, thereby enhancing vascular permeability *in vitro* and *in viv*o ([@B50]). Our data showed that KVECs have 11-fold upregulated expression of LAMC2. Moreover, as with SERPINA3, LPS treatment of normal VECs increased their LAMC2 expression. These findings together with the known activities of LAMC2 suggest that LAMC2 overexpression in KVECs may encourage endothelial hyperpermeability, which in turn may prolong the inflammatory stage, thereby promoting keloid formation and progression. Since LAMC2 promotes the proliferation and survival of cancer cells ([@B19]; [@B50]), and keloids are characterized by excessive fibroblast proliferation and resistance to apoptosis ([@B18]), we also asked whether LAMC2 secretion by VECs could promote keloid fibroblast proliferation and downregulate apoptosis. However, culturing normal fibroblasts with LAMC2 had no effect on these properties. Further studies on the potential underlying mechanisms are warranted.

Because keloids are elastic fibrotic lesions that are formed by excessive deposition of ECM components, it is hard to digest keloids and isolate cells with small populations such as VECs. While VECs have been isolated from soft organs or VECs-rich tumors ([@B37]; [@B34]; [@B14]), only one study has reported the isolation of VECs from (hypertrophic) scars ([@B55]). However, recent technological advances, namely, the application of gentle digestion followed by magnetic sorting, allowed us to isolate VECs from keloid tissues. The gentle digestion contributes to the high cell survival rates and the two magnetic cell sorting-based isolation steps that, respectively, removed the many CD45-positive cells and fibroblasts and positively selected the CD31-positive VECs led to very pure VECs populations. In the future, similar recent advances in this technology will be used to isolate and analyze targeted single cells.

This study has some limitations. First, not all VECs in keloids express CD31. Second, the up- and down-regulated genes do not simply reflect the activities of KVECs: rather, they are likely to reflect the sum of not only KVEC behavior but also systemic and local inflammatory factors. More functional experiments in which these genes are knocked out or down are required.

Conclusion {#S5}
==========

This is the first study to analyze the expression profiles of VECs from keloids. It showed that two genes involved in immune cell, ECM, and endothelial regulation, namely, SERPINA3 and LAMC2, are highly upregulated in KVECs compared to in NVECs. These findings may not only help to clarify how keloids develop but they may also be useful targets for anti-keloid therapies that are effective at different stages after onset. For example, inhibiting LAMC2 early after onset may prevent the vascular permeability and prolongation of inflammation that drives keloid growth. Similarly, inhibiting SERPINA3 in well-established keloids may promote immune responses and the degradation of the ECM, thereby reducing the keloid mass and/or preventing its further outgrowth. More detailed functional analyses of the VECs in keloids are warranted.
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